HEALIUS LIMITED — Director's Dealing 2023

Dec 18, 2023

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maxine Jaquet
Date of last notice	6 September 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances givingrise to the relevant interest.	As shown
Date of change	14 December 2023
No. of securities held prior tochange	409,083 Ordinary Shares3,335,611 Options371,859 Performance Rights
Class	Ordinary Shares
Number acquired	112,078 Ordinary Shares
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration
Note: If consideration is non-cash, provide details	$1.20 per share
and estimated valuation
	521,161 Ordinary Shares
No. of securities held after	3,335,611 Options
change	371,859 Performance Rights
Nature of changeExample: on-market trade, off-market trade,exercise of options, issue of securities under	Acceptance of pro rata offer to acquire securities underthe Healius Retail Entitlement Offer of its fullyunderwritten 1 for 3.65 pro-rata accelerated non-
dividend reinvestment plan, participation in buy-back	renounceable entitlement offer of new fully paid ordinaryshares as announced on Monday, 20 November 2023.

Part 2 – Change of director’s interests in contracts Not applicable

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed above traded during a[+] closed period where N/A prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date N/A was this provided?

Authorised by the Company Secretary.

Mary Weaver Company Secretary Date: 19 December 2023

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011